HC Wainwright Boosts Earnings Estimates for DBV Technologies

DBV Technologies S.A. (NASDAQ:DBVT) – Equities research analysts at HC Wainwright upped their FY2027 earnings estimates for DBV Technologies in a report issued on Wednesday, December 17th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($1.50) for the year, up from their previous estimate of ($1.55). The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2028 earnings at ($0.05) EPS and FY2029 earnings at $2.25 EPS.

Other equities analysts also recently issued research reports about the company. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Guggenheim reiterated a “buy” rating and set a $51.00 price target (up previously from $35.00) on shares of DBV Technologies in a research report on Wednesday. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday. Finally, Citizens Jmp upped their target price on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $35.38.

DBV Technologies Price Performance

Shares of DBVT opened at $22.76 on Friday. The company has a market capitalization of $914.04 million, a P/E ratio of -4.40 and a beta of -1.10. DBV Technologies has a one year low of $2.92 and a one year high of $26.18. The business’s 50 day simple moving average is $15.38 and its 200-day simple moving average is $11.83.

Insider Activity

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50. Following the transaction, the insider owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. This trade represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.44% of the company’s stock.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of DBVT. New York State Common Retirement Fund bought a new stake in shares of DBV Technologies during the 3rd quarter valued at $34,000. Two Sigma Investments LP bought a new position in shares of DBV Technologies in the 3rd quarter worth $167,000. Citadel Advisors LLC acquired a new stake in shares of DBV Technologies during the third quarter worth $220,000. DLD Asset Management LP bought a new stake in DBV Technologies in the third quarter valued at about $250,000. Finally, Nan Fung Trinity HK Ltd. acquired a new position in DBV Technologies in the second quarter valued at about $340,000. 71.74% of the stock is owned by institutional investors.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: Phase‑III win in peanut allergy improves commercial/clinical outlook — a Bioworld report says DBV’s VIT® program delivered a positive Phase III result, a material de‑risking event for a lead program that can drive future revenue and re‑rating. Vitesse finesse pays off: DBV wins in peanut allergy phase III
• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts, signaling stronger long‑term profitability expectations (FY2027–FY2029 upgrades). That upward revision likely helped investor sentiment and price momentum. HC Wainwright Expects Stronger Earnings for DBV Technologies
• Positive Sentiment: Additional bullish analyst notes and coverage changes — the stock was reported to hit a new 1‑year high after analyst upgrades, and coverage consensus sits around a “Moderate Buy,” with at least one firm (Citizens JMP) forecasting strong price appreciation. Those actions typically boost retail/institutional interest. DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Market consensus EPS remains deeply negative for the current year (consensus ~($7.05) EPS), so while upgrades are meaningful, the company is still transitioning from loss‑making to profitable — investors should watch upcoming milestones and cash runway closely.
• Negative Sentiment: Major shareholder Bpifrance Epic sold large blocks of stock on Dec 17–18 (combined ~3.37M shares sold across two days, materially reducing its stake). Large insider/major‑holder selling can pressure the stock and signal liquidity‑driven exits even when fundamentals improve. SEC filing: Bpifrance Epic Insider Sales SEC Filing
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (worse near‑term profitability view), a reminder that boutique analysts still see near‑term execution and cash burn risk — this can cap upside until revenue/profitability is proven.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.